Tetraphase - Top 15 Biotech VC Deals of 2010

Company: Tetraphase Pharmaceuticals
Based: Watertown, MA
Amount: $45M

Investors: Excel Venture Management, CMEA Ventures, Fidelity Biosciences, Flagship Ventures, Mediphase Venture Partners and Skyline Ventures

Scoop: 2010 Fierce 15 winner Tetraphase early last summer brought in a $45 million C round--a hefty chunk of cash that will open a development runway stretching out up to two-and-a-half years. CEO Guy Macdonald told FierceBiotech the company will put its technology for developing a better breed of tetracycline antibiotics to the clinical development test, taking a lead program--TP-434--through Phase II and ushering two more into the clinic. By the end of this stretch, the biotech should be able to position itself for a collaboration deal and possibly even an IPO.


Tetraphase - Top 15 Biotech VC Deals of 2010

Suggested Articles

Akcea CEO Paula Soteropoulos, Chief Business Officer Sarah Boyce and Chief Operating Officer Jeff Goldberg are bidding the company adieu.

Weeks after getting off a major $110 million series B round, well-funded Passage Bio has grabbed a new C-suite member on top of its cash haul.

The deal gives Clovis the ex-Europe rights to a cancer candidate set to enter the clinic in the second half of next year.